MeCP2 is required for global heterochromatic and nucleolar changes during activity-dependent neuronal maturation

Neurobiology of Disease

Volumn 43, Issue 1, 2011, Pages 190-200

  Singleton, Malaika K ^a   Gonzales, Michael L ^a   Leung, Karen N ^a   Yasui, Dag H ^a   Schroeder, Diane I ^a   Dunaway, Keith ^a   LaSalle, Janine M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chromatin; DNA methylation; Epigenetic; Maturation; MeCP2; Neurodevelopmental; Neuronal; Nucleoli; Rett syndrome

Indexed keywords

METHYL CPG BINDING PROTEIN 2; METHYL CPG BINDING PROTEIN 2E1; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; CELL MATURATION; CONTROLLED STUDY; DEPOLARIZATION; FEMALE; GENE MUTATION; GENE TARGETING; HETEROCHROMATIN; HUMAN; HUMAN CELL; MALE; MOUSE; NERVE CELL; NEWBORN; NONHUMAN; NUCLEAR SIZE; NUCLEOLUS; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEOLUS; CELLS, CULTURED; FEMALE; HETEROCHROMATIN; HUMANS; MALE; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEURONS;

EID: 79955955059     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.03.011     Document Type: Article

References (40)

1. Adegbola A.A., Gonzales M.L., Chess A., LaSalle J.M., Cox G.F. A novel hypomorphic MECP2 point mutation is associated with a neuropsychiatric phenotype. Hum. Genet. 2009, 124:615-623.
2. Akhmanova A., et al. Characterisation of transcriptionally active and inactive chromatin domains in neurons. J. Cell Sci. 2000, 113(Pt 24):4463-4474.
3. Amir R.E., et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
4. Ballas N., et al. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 2005, 121:645-657.
5. Balmer D., et al. Elevated methyl-CpG-binding protein 2 expression is acquired during postnatal human brain development and is correlated with alternative polyadenylation. J. Mol. Med. 2003, 81:61-68.
6. Bienvenu T., et al. Spectrum of MECP2 mutations in Rett syndrome. Genet. Test 2002, 6:1-6.
7. Boisvert F.M., et al. The multifunctional nucleolus. Nat. Rev. Mol. Cell Biol. 2007, 8:574-585.
8. Braunschweig D., et al. X-chromosome inactivation ratios affect wild-type MeCP2 expression within mosaic Rett syndrome and Mecp2?/+ mouse brain. Hum. Mol. Genet. 2004, 13:1275-1286.
9. Brero A., et al. Methyl CpG-binding proteins induce large-scale chromatin reorganization during terminal differentiation. J. Cell Biol. 2005, 169:733-743.
10. Caperta A.D., et al. Relationships between transcription, silver staining, and chromatin organization of nucleolar organizers in Secale cereale. Protoplasma 2007, 232:55-59.
11. Chen R.Z., et al. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 2001, 27:327-331.
12. Chen W.G., et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003, 302:885-889.
13. Davison A.N., Dobbing J. Applied Neurochemistry 1968, Blackwell Scientific, Oxford, Edinburgh.
14. Ghosh R.P., et al. MeCP2 binds cooperatively to its substrate and competes with histone H1 for chromatin binding sites. Mol Cell Biol. 2010, 30:4656-4670.
15. Gonzales M.L., LaSalle J.M. The role of MeCP2 in brain development and neurodevelopmental disorders. Curr. Psychiatry Rep. 2010, 12:127-134.
16. Guetg C., et al. The NoRC complex mediates the heterochromatin formation and stability of silent rRNA genes and centromeric repeats. EMBO J. 2010, 29:2135-2146.
17. Guy J., et al. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 2001, 27:322-326.
18. Huppke P., et al. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. Hum. Mol. Genet. 2000, 9:1369-1375.
19. Ishibashi T., et al. MeCP2 preferentially binds to methylated linker DNA in the absence of the terminal tail of histone H3 and independently of histone acetylation. FEBS Lett. 2008, 582:1157-1162.
20. Klose R.J., et al. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol. Cell 2005, 19:667-678.
21. Kumar A., et al. Analysis of protein domains and Rett syndrome mutations indicate that multiple regions influence chromatin-binding dynamics of the chromatin-associated protein MECP2 in vivo. J. Cell Sci. 2008, 121:1128-1137.
22. Lewis J.D., et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992, 69:905-914.
23. Manuelidis L. Active nucleolus organizers are precisely positioned in adult central nervous system cells but not in neuroectodermal tumor cells. J. Neuropathol. Exp. Neurol. 1984, 43:225-241.
24. Manuelidis L. Different central nervous system cell types display distinct and nonrandom arrangements of satellite DNA sequences. Proc. Natl Acad. Sci. U.S.A. 1984, 81:3123-3127.
25. Manuelidis L. Indications of centromere movement during interphase and differentiation. Ann. NY Acad. Sci. 1985, 450:205-221.
26. Martinowich K., et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003, 302:890-893.
27. Martou G., De Boni U. Nuclear topology of murine, cerebellar Purkinje neurons: changes as a function of development. Exp. Cell Res. 2000, 256:131-139.
28. Mnatzakanian G.N., et al. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat. Genet. 2004, 36:339-341.
29. Nan X., et al. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res. 1993, 21:4886-4892.
30. Nikitina T., et al. MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome. J. Biol. Chem. 2007, 282:28237-28245.
31. Nikitina T., et al. Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. Mol. Cell. Biol. 2007, 27:864-877.
32. Peddada S., et al. Inhibitors of differentiation (ID1, ID2, ID3 and ID4) genes are neuronal targets of MeCP2 that are elevated in Rett syndrome. Hum. Mol. Genet. 2006, 15:2003-2014.
33. Santoro R., et al. The nucleolar remodeling complex NoRC mediates heterochromatin formation and silencing of ribosomal gene transcription. Nat. Genet. 2002, 32:393-396.
34. Shahbazian M.D., et al. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum. Mol. Genet. 2002, 11:115-124.
35. Shahbazian M.D., Zoghbi H.Y. Rett syndrome and MeCP2: linking epigenetics and neuronal function. Am. J. Hum. Genet. 2002, 71:1259-1272.
36. Skene P.J., et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 2010, 37:457-468.
37. Solovei I., et al. Positional changes of pericentromeric heterochromatin and nucleoli in postmitotic Purkinje cells during murine cerebellum development. Cytogenet. Genome Res. 2004, 105:302-310.
38. Thatcher K.N., LaSalle J.M. Dynamic changes in Histone H3 lysine 9 acetylation localization patterns during neuronal maturation require MeCP2. Epigenetics 2006, 1:24-31.
39. Zhou Z., et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006, 52:255-269.
40. Zoghbi H.Y. MeCP2 dysfunction in humans and mice. J. Child Neurol. 2005, 20:736-740.